Article

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade Glioma

2025-05-16

Abstract excerpt

<title>Abstract</title> <p>Purpose While immunotherapy has transformed treatment in multiple solid tumors, its efficacy in high-grade glioma remains limited. Understanding the molecular and clinical factors that influence glioma’s response to immunotherapy is essential to improving outcomes. Methods We identified patients with recurrent glioblastoma or astrocytoma, IDH-mutant grade 4, who had been treated with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 372679e9-d4aa-5539-b19b-a2305e2b6b88
DOI: 10.21203/rs.3.rs-6649860/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade GliomaDOI 10.21203/rs.3.rs-6649860/v1Read

Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.Semantic proximity Read

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade gliomaSemantic proximity Read

Landscape of Genomic Alterations inIDHWild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic FactorSemantic proximity Read

Overview of prognostic factors in adult glioma; a 10-year experience at a single institutionSemantic proximity Read

Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.Semantic proximity Read

Novel interferon-gamma-related 2-gene signature predicts outcome and responsiveness to immune checkpoint blockade in gliomaSemantic proximity Read

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read

Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.Semantic proximity Read

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma CohortsSemantic proximity Read

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Semantic proximity Read